A novel prognostic scoring system for NLPHL.

In this issue of Blood, Hartmann and colleagues from the German Hodgkin Study Group (GHSG) conducted a review of pathologic features and clinical data from 423 patients with nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) treated across 9 of their prospective clinical trials. First, they determined that patients with histologic variants have a higher chance of having advanced-stage disease and a greater risk for disease progression or relapse at 5 years. Second, they were able to establish a prognostic scoring model that defines 3 discrete risk groups based on the factors of variant histopathologic growth pattern, low serum albumin, and male gender.